Back

Mexiletine shortened QTc interval in an age-dependent manner but suppressed ventricular arrhythmias at all age in children with long QT syndrome type 8

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Clinical and experimental arrhythmia treatments Antiarrhythmic Drug Treatment ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Junichi Ozawa

Niigata University Graduate School of Medical and Dental Sciences, Niigata (Japan)

8 More presentations in this session

Presentation thumbnail
Efficacy and safety of ultrasound guided stellate ganglion block: developing new clinical indications beyond electrical storm
Doctor A. Morena (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Atrial and ventricular arrhythmias in young, lifelong and retired elite endurance athletes
Doctor P. D'Ambrosio (Fitzroy, AU)
Abstract Slides Video
Presentation thumbnail
Analysis of safety and outcome of use of NOAC in intracardiac thrombi over warfarin
Doctor O. Al-assaf (Dubai, AE)
Abstract Slides Video
Presentation thumbnail
Amiodarone-related thyroid dysfunction and associated outcomes in patients with heart failure - a matched case-control study
Doctor S. Ali (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Association between preprocedural thromboembolic or bleeding events under oral anticoagulation therapy and mid-term outcomes after percutaneous left atrial appendage closure
Doctor H. Sumiyoshi (Kamogawa, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Clinical and experimental arrhythmia treatments

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Differences in response to treatment with a sodium channel antagonists in arrhythmic DCM caused by the SCN5A R222Q versus R814W variant
thumbnail
Congress Presentation
Efficacy and safety of HERG channel agonists for treatment of Long QT Syndrome type 8
thumbnail
Congress Presentation
Sulcardine, an investigational multichannel blocker for atrial fibrillation with uniquely intense JTp inhibition to enhance safety

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources